Analysts think AVTX stock price could increase by 218%
Aug 01, 2024, 6:25 AM
-36.94%
What does AVTX do
Avalo Therapeutics Inc, a clinical-stage biotech firm based in Rockville, Maryland with 20 employees, focuses on developing therapies targeting the LIGHT-signaling network for immune dysregulation. Their key products include AVTX-002 for various disorders and AVTX-008, a BTLA agonist fusion protein, with the company going public in 2015.
3 analysts think AVTX stock price will increase by 218.18%. The current median analyst target is $35.70 compared to a current stock price of $11.22. The lowest analysts target is $35.35 and the highest analyst target is $36.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
